Evolent Health (NYSE:EVH)‘s stock had its “overweight” rating restated by research analysts at KeyCorp in a research note issued on Thursday, The Fly reports. They currently have a $32.00 price target on the technology company’s stock. KeyCorp’s price target indicates a potential upside of 22.37% from the stock’s previous close. The analysts noted that the move was a valuation call.

Several other equities analysts have also recently commented on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $25.00 price target on shares of Evolent Health in a research report on Tuesday, August 7th. Zacks Investment Research cut shares of Evolent Health from a “buy” rating to a “hold” rating in a research report on Wednesday, July 25th. Piper Jaffray Companies initiated coverage on shares of Evolent Health in a research report on Monday, June 4th. They issued an “overweight” rating and a $30.00 price target for the company. ValuEngine raised shares of Evolent Health from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. Finally, TheStreet raised shares of Evolent Health from a “d+” rating to a “c-” rating in a research report on Monday, June 4th. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. Evolent Health currently has an average rating of “Buy” and an average target price of $28.33.

Evolent Health stock opened at $26.15 on Thursday. Evolent Health has a fifty-two week low of $10.30 and a fifty-two week high of $26.35. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.59 and a quick ratio of 2.59. The company has a market capitalization of $2.03 billion, a P/E ratio of -37.36 and a beta of 1.22.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, August 7th. The technology company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. Evolent Health had a negative net margin of 9.84% and a negative return on equity of 1.82%. The company had revenue of $144.51 million during the quarter, compared to analysts’ expectations of $141.90 million. sell-side analysts expect that Evolent Health will post -0.34 EPS for the current year.

In other news, CEO Frank J. Williams sold 41,015 shares of Evolent Health stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $24.02, for a total transaction of $985,180.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Seth Blackley sold 164,139 shares of Evolent Health stock in a transaction on Thursday, July 5th. The stock was sold at an average price of $22.30, for a total transaction of $3,660,299.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 461,315 shares of company stock valued at $10,491,814. Corporate insiders own 4.82% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY raised its stake in Evolent Health by 12.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 22,031 shares of the technology company’s stock worth $464,000 after acquiring an additional 2,459 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in Evolent Health by 16.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 21,773 shares of the technology company’s stock worth $458,000 after acquiring an additional 3,150 shares in the last quarter. Legal & General Group Plc raised its stake in Evolent Health by 16.8% during the 1st quarter. Legal & General Group Plc now owns 26,437 shares of the technology company’s stock worth $377,000 after acquiring an additional 3,811 shares in the last quarter. Rhumbline Advisers raised its stake in Evolent Health by 8.2% during the 1st quarter. Rhumbline Advisers now owns 57,923 shares of the technology company’s stock worth $825,000 after acquiring an additional 4,370 shares in the last quarter. Finally, Swiss National Bank increased its stake in Evolent Health by 4.8% in the first quarter. Swiss National Bank now owns 104,000 shares of the technology company’s stock valued at $1,482,000 after purchasing an additional 4,800 shares during the period.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

See Also: Index Funds

The Fly

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.